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0207: RENAL TRANSPLANTATION USING DONOR GRAFTS WITH COM-
PLETE URETERAL DUPLICATION
H. West*, R. Singh, A. Bagul, T. Doughman, A. Rizzello. Leicester General
Hospital, Leicester, UK.
Aim: Renal transplantation with duplication of the ureter is seldom re-
ported. Multiple renal arteries or veins are more common. The purpose of
this study was to evaluate the outcome of renal transplants using donor
grafts with complete ureteral duplication.
Method: From 1975-2015 over 2000 patients received a renal transplant.
Since 1990 eleven patients, eight male, mean age 54.8 +/- 13.05 SD years,
received renal transplants from donors with complete ureteral duplication.
Eight were allocated by the National UK Transplant Scheme and threewere
from live donors. In eight patients the ureters were implanted separately at
the bladder dome using an onlay extravesical ureteroneocystostomy
(modiﬁed Lich technique) each with a separate J-J stent which was
removed at 6 weeks according to protocol. In three patients the two ure-
ters were spatulated and sutured together. Five donor kidneys had dupli-
cation of the renal vessels.
Result: There was no history of functional impairment, recurrent urinary
tract infection, ureteric strictures or leaks or graft loss. Two patients had
previous renal transplants.
Conclusion: Donor kidneys with ureteral duplication may be used for
transplantation and did not increase complication rates. They yielded
equal outcomes to single ureter donor kidneys. The Lich-Gregoir technique
may provide excellent results.http://dx.doi.org/10.1016/j.ijsu.2016.08.3790467: THE USE OF TRANEXAMIC ACID IN THE PERIOPERATIVE MAN-
AGEMENT OF PATIENTS UNDERGOING ORTHOTOPIC LIVER
TRANSPLANTATION
E. Chew, E. Christopher*, L. Davidson, J. Fretwell, J. Kiang, A. Shearer, L. Tan,
S. Train. University of Edinburgh, Edinburgh, UK.
Introduction: Haemorrhage is a major cause of mortality following
orthotopic liver transplantation (OLT). Antiﬁbrinolytics e.g. aprotinin could
be administered to reduce blood loss and lower risks associated with
transfusion. Although aprotinin used to be the standard antiﬁbrinolytic
administered in OLT, its use has been associated with higher mortality risk.
Aim: To investigate whether antiﬁbrinolytic tranexamic acid (TA) is
justiﬁable as a substitute to aprotinin in routine OLT.
Method: Four databases eMedline, Embase, Scopus andWeb of Science e
were used to ﬁnd relevant studies. The inclusion criteria ensured that
studies were full clinical trials comparing TA with placebo/other
antiﬁbrinolytics.
Result: Seven studies met the inclusion criteria. Results were qualitatively
categorised into the effects of TA on blood loss, transfusion requirements,
coagulation, and adverse effects such as mortality.
Discussion: TA signiﬁcantly reduces blood loss and transfusion re-
quirements and is better at coagulation compared to placebo. While its
ability to reduce blood loss and transfusion requirements pales in com-
parison to aprotinin, it is better at achieving coagulation than aprotinin.
None of the studies were sufﬁciently powered to measure safety and
mortality.
Conclusion: TA is a viable alternative in OLT that would be more beneﬁcial
than forgoing the administration of an antiﬁbrinolytic.http://dx.doi.org/10.1016/j.ijsu.2016.08.3800468: LIVING ORGAN VERSUS CADAVERIC DONATION: A COMPARISON
OF OUTCOMES FOLLOWING RENAL TRANSPLANTATION ACCORDING
TO RECIPIENT BODY MASS INDEX AND DONATION TYPE
A. Mehta 1,*, A. Marriott 1, A. Ghazanfar 2. 1 St George's, University of London,
London, UK; 2 St George's Hospital, London, UK.
Aim: This study aims to determine whether a combination of donation
type and obesity (Body Mass Index 30kg/m2) can affect outcomes
following renal transplant.
Method: A consecutive series of renal transplants (2008-2013) were
audited with patients divided into three cohorts based on BMI (kg/m2)
[Cohort A<25, B 25-29.99, C30] and then Living vs. Cadaveric donation.
We recorded perioperative complications within 90 days and graft survival
at 3 years.
Result: Sample¼610 transplant recipients (living donation¼275, cadaveric
donation¼335, excluded¼24). -One-way ANOVA proved signiﬁcant
(p¼0.024, F¼3.764) for number of complications per patient in Cohort C
(average ¼1.5) in comparison to Cohort A (average ¼1.0) for transplants
with cadaveric donation only (p¼0.014 Bonferroni-adjusted). -For
complication type, chi-square proved signiﬁcant for Collection (p¼0.009)
and Lymphocele (p¼0.005) for transplants with cadaveric donation. -Graft
survival: Censored data shows a minimum 7% increase at 3 years for living
donation transplants in any BMI cohort in comparison to cadaveric
donation.
Conclusion: Short-term: the combination of cadaveric kidney donation
and obese recipient should be viewed as higher risk, with additional
informed consenting and multidisciplinary planning. Long-term: living
organ donation appears substantially better in terms of graft survival and
obesity does not appear to have an effect.http://dx.doi.org/10.1016/j.ijsu.2016.08.381
0580: ALEMTUZUMAB INDUCTION ALLOWS BETTER REJECTION FREE
GRAFT SURVIVAL INCOMPARISON TO BASILIXIMAB ALBEIT INCREASED
POST TRANSPLANT VIRALINFECTIONS
V. Siddagangaiah 1, H. Sharma 2, N. Lal 3,*, J. Rai 1, M. Howse 1, D. Ridgway 1,
A. Sharma 1, A. Hammad 1, S. Mehra 1. 1Royal Liverpool and Broadgreen
University Hospitals, Liverpool, UK; 2Manchester Royal Inﬁrmary, Manchester,
UK; 3 School of Medicine, University of Liverpool, Liverpool, UK.
Background: 3C study concluded that in comparison to basiliximab,
alemtuzumab induction reduces the risk of biopsy proven acute rejection
(BPAR) in renal transplant recipients.
Aim: To compare alemtuzumab and basiliximab induction followed by
standard two drug maintenance immunosuppression to assess rejection &
infection rate.
Method: Data was collected retrospectively from patients transplanted
between 1/08/2009 to 31/12/2013. 436 patients were analyzed; 235
received basiliximab, 198 received alemtuzumab& data was not available
for 3 patients. Tacrolimus and mycophenolate mofetil were used as
maintenance immunosuppression in both groups.
Result: Review of the data showed no signiﬁcant differences for de-
mographic details, graft & patient survival. Basiliximab group had
increased incidence of BPAR, 22.1% as compared to Alemtuzumab, 7.5%
(Yates correction <0.001, Fischers Exact test one tailed p<.0001). Median
creatinine level at 6 weeks was 128± 21 mmol/L (Basiliximab) & 115± 16
mmol/L (Alemtuzumab). However, incidence of Viral infections was higher
in the Alemtuzumab group vs Basiliximab (Fischer Exact test one tailed
p<0.0002, Pearson Test p< 0.0004).
Conclusion: Alemtuzumab induction signiﬁcantly reduces the incidence
of rejection but at the cost of increased viral infections. Our Study cor-
roborates the 3C Trial ﬁndings. Further review of data over timewill assess
long term graft outcomes.http://dx.doi.org/10.1016/j.ijsu.2016.08.382
